







Ċ







Abbott

The FreeStyle Libre flash glucose monitoring system is indicated for measuring interstitial fluid glucose levels in adults aged 18 years and older with diabetes mellitus. Always read and follow the label/insert.

The FreeStyle Libre 2 flash glucose monitoring system is indicated for measuring interstitial fluid glucose levels in people aged 4 years and older with diabetes mellitus. Always read and follow the label/insert.

The FreeStyle LibreLink app and the FreeStyle Libre 2 app are only compatible with certain mobile devices and operating systems. Please check the website for more information about device compatibility before using the apps.

* 60-minute warm-up required when applying the sensor.

+ Sensor is water-resistant in up to 1 metre (3 feet) of water. Do not immerse longer than 30 minutes. Not to be used above 10,000 feet.

When it comes to glucose monitoring options, times have changed



SMBG* devices are commonly used, but do they make a difference?



Users do not test as often as they should

Only **1/3 adhere** to the frequency of SMBG recommended by their healthcare provider (HCP)¹



Users do not achieve their optimal glycemic control

1/2 of Canadians with diabetes do not achieve their A1C target of $\leq 7\%^2$

But there's another proven option for glucose monitoring...

	1

Real-world evidence shows that patients using the **FreeStyle Libre system** scan on average **12 times per day**³



And higher rates of scanning are associated with **improved glucose control**³



Thousands of Canadians use and trust the FreeStyle Libre portfolio of products, prescribed by your peers³

Data collected with the FreeStyle Libre system. The FreeStyle Libre 2 system has the same features as the FreeStyle Libre system but with optional real-time glucose alarms. Therefore, study data are applicable to both products. SMBG, self-monitoring of blood glucose.

* Also known as capillary blood glucose, or CBG.⁴

References: 1. Vincze G, Barner JC, Lopez D. Factors associated with adherence to self-monitoring of blood glucose among persons with diabetes. *Diabetes Educ.* 2004;30(1):112-125. **2.** Leiter LA, Berard L, Bowering CK, et al. Type 2 diabetes mellitus management in Canada: is it improving? *Can J Diabetes.* 2013;37(2):82-89. **3.** Berard L, Virdi N, Dunn TC. Canadian real-world analysis of flash glucose monitoring and impact on glycemic control. Poster presented at: Diabetes Canada Conference; October 2-5, 2019; Winnipeg, MB. **4.** Cheng AYY, Feig DS, Ho J, Siemens R. Blood glucose monitoring in adults and children with diabetes: update 2021. *Can J Diabetes.* 2021;45(7):580-587.

Patients with T2D benefit from the FreeStyle Libre portfolio of products



SMBG shows the current blood glucose level



By filling in the gaps, the FreeStyle Libre portfolio of products will help make the invisible, visible^{1,2}





Data collected with the FreeStyle Libre system. The FreeStyle Libre 2 system has the same features as the FreeStyle Libre system but with optional real-time glucose alarms. Therefore, study data are applicable to both products. SMBG, self-monitoring of blood glucose; T2D, type 2 diabetes.

References: 1. Dunn TC, Hayter GA, Doniger KJ, Wolpert HA. Development of the likelihood of low glucose (LLG) algorithm for evaluating risk of hypoglycemia: a new approach for using continuous glucose data to guide therapeutic decision making. *J Diabetes Sci Technol.* 2014;8(4):720-730. **2.** Maran A, Esposito K, Toni S, Giordano C. Ambulatory glucose profile applied to flash glucose monitoring in real life: an expert opinion. *J Diabetes Sci Technol.* 2017;11(3):633-634.

Isolated numbers are not enough...

SMBG: Offers only a small A1C reduction in comparison to those who do not test at all-absolute A1C reduction of 0.2% to 0.5%¹ Not shown to affect patient satisfaction, general well-being, or general health-related guality of life¹

Treatment decisions should be based on HCP recommendations.

Data collected with the FreeStyle Libre system. The FreeStyle Libre 2 system has the same features as the FreeStyle Libre system but with optional real-time glucose alarms. Therefore, study data are applicable to both products. HCP, healthcare provider; SMBG, self-monitoring of blood glucose; T2D, type 2 diabetes.

References: 1. Berard LD, Siemens R, Woo V. Diabetes Canada 2018 clinical practice guidelines for the prevention and management of diabetes in Canada: monitoring glycemic control. *Can J Diabetes*. 2018;42(suppl 1):S47-S53.
2. Kröger J, Fasching P, Hanaire H. Three European retrospective real-world chart review studies to determine the effectiveness of flash glucose monitoring on HbA1c in adults with type 2 diabetes. *Diabetes Ther*. 2020;11(1): 279-291.
3. Haak T, Hanaire H, Ajjan R, Hermanns N, Riveline JP, Rayman G. Flash glucose-sensing technology as a replacement for blood glucose monitoring for the management of insulin-treated type 2 diabetes: a multicenter, open-label randomized controlled trial. *Diabetes Ther*. 2017;8(1):55-73.
4. Hood K, DiMeglio L, Riddle M. Putting continuous glucose monitoring to work for people with type 1 diabetes. *Diabetes Care*. 2020;43(1):19-21.

The FreeStyle Libre system:

Clinically proven to significantly reduce A1C by 0.9% in patients with T2D²

Helps patients **understand the impact of food, medication, or exercise** on their glucose levels^{3,4}



For illustration purposes only. Coloured arrows and dots will not appear on actual phone screen.

In addition, the FreeStyle Libre system **helps patients** feel more engaged in managing their diabetes^{3,4}

Impact of different testing and treatment options on A1C levels in T2D

Regardless of therapy, **a wide range** of patients with T2D can benefit from significant A1C reduction by using the FreeStyle Libre portfolio of products¹

Class	Relative A1C lowering ² ($\frac{1}{2} \approx 0.5\%$ reduction)	A1C reduction ranges
SMBG testing	to	0.2% to 0.5% ³
Metformin	₽₽	1.12%4
Other orals (excluding metformin)	to	0.5% to 1.25%⁵
GLP-1s	to to	0.78% to 1.9% ⁶

Additional lowering

ClassRelative A1C lowering²
 $\sim 0.5\%$ reduction)A1C reduction rangesInsulinImage: Image: Im

Data collected with the FreeStyle Libre system. The FreeStyle Libre 2 system has the same features as the FreeStyle Libre system but with optional real-time glucose alarms. Therefore, study data are applicable to both products.
GLP-1, glucose-like peptide-1 agonist; T2D, type 2 diabetes. **References: 1.** Berard L, Virdi N, Dunn TC. Canadian real-world analysis of flash glucose monitoring and impact on glycemic control. Poster presented at: Diabetes Canada Conference; October 2-5, 2019; Winnipeg, MB. **2.** Lipscombe L, Booth G, Butalia S, et al. Diabetes
Canada 2018 clinical practice guidelines for the prevention and management of diabetes in Canada: pharmacologic glycemic management of type 2 diabetes in adults. *Can J Diabetes*. 2018;42(suppl 1):S88-S103. **3.** Berard LD, Siemens R, Woo V. Diabetes Canada 2018 clinical practice guidelines for the prevention and management of diabetes in Canada: nonitoring glycemic control. *Can J Diabetes*. 2018;42(suppl 1):S47-S53. **4.** Hirst JA, Roberts NW, Farmer AJ, Stevens RJ, Ali R. Quantifying the effect of metformin treatment and dose on glycemic control. *Diabetes Cane*. 2012;35(2):446-454. **5.** Sherifali D, Cheng JE, Nerenberg K, Caratin HC, Pulleaverum E. The affect of cral avait diabetes aparts on A1C levels. *Diabetes*.

Farmer AJ, Stevens RJ, Ali R. Quantifying the effect of metformin treatment and dose on glycemic control. *Diabetes Care.* 2012;35(2):446-454. **5.** Sherifali D, Cheng JE, Nerenberg K, Gerstein HC, Pullenayegum E. The effect of oral antidiabetic agents on A1C levels. *Diabetes Care.* 2010;33(8):1859-1864. **6.** Trujillo JM, Nuffer W, Ellis SL. GLP-1 receptor agonists: a review of head-to-head clinical studies. *Ther Adv Endocrinal Metab.* 2015;6(1):19-28. **7.** Miller E, Brandner L, Wright E. HbA1c reduction after initiation of the FreeStyle Libre system in type 2 diabetes patients on long-acting insulin or non-insulin therapy. *Diabetes.* 2020;69(suppl 1): 84-LB. **8.** Dailey G, Admane K, Mercier F, Owens D. Relationship of insulin detemir. *Diabetes Technol Ther.* 2010;12(12):1019-1027. **9.** Kröger J, Fasching P, Hanaire H. Three European retrospective real-world chart review studies to determine the effectiveness of flash glucose monitoring on HbA1c in adults with type 2 diabetes. *Diabetes Ther.* 2020;11(1):279-291.

Don't forget the importance of Time in Range



Diabetes Canada Guideline recommendations

Canadian Clinical Practice Guidelines recommend that most patients with diabetes should spend at least 70% of their **Time in Range**¹



The **FreeStyle Libre** portfolio of products automatically calculates the percentage of time a person spends in, above, or below their target range, **to help empower them**

References: 1. Cheng AYY, Feig DS, Ho J, Siemens R. Blood glucose monitoring in adults and children with diabetes: update 2021. *Can J Diabetes.* 2021;45(7):580-587. 2. Vigersky RA, McMahon C. The relationship of hemoglobin A1c to time-in-range in patients with diabetes. *Diabetes Technol Ther.* 2019;21(2):81-85. 3. Beck RW, Bergenstal RM, Riddlesworth TD, et al. Validation of time in range as an outcome measure for diabetes clinical trials. *Diabetes Care.* 2019;42(3):400-405.



Benefits for you and your patients



Reduced A1C

FreeStyle Libre helps patients significantly reduce their A1C¹



Easy to use²

With a painless,³ 1-second scan, patients see where they've been, where they are, and where they're going



Easy to wear

Small, discreet sensor that is easy to apply and comfortable to wear $^{\rm 3}$ for up to 14 days



Easy to prescribe

Prescription pads also available—just ask your Abbott representative

Data collected with the FreeStyle Libre system. The FreeStyle Libre 2 system has the same features as the FreeStyle Libre system but with optional real-time glucose alarms. Therefore, study data are applicable to both products.

References: 1. Kröger J, Fasching P, Hanaire H. Three European retrospective real-world chart review studies to determine the effectiveness of flash glucose monitoring on HbA1c in adults with type 2 diabetes. *Diabetes Ther.* 2020;11(1):279-291. **2.** Data on file, Abbott Diabetes Care Inc. **3.** Haak T, Hanaire H, Ajjan R, Hermanns N, Riveline JP, Rayman G. Flash glucose-sensing technology as a replacement for blood glucose monitoring for the management of insulin-treated type 2 diabetes: a multicenter, open-label randomized controlled trial. *Diabetes Ther.* 2017;8(1):55-73.

Recommend the FreeStyle Libre or FreeStyle Libre 2 system for your patients with T2D today



Available for people aged 18 and older with diabetes Use with the FreeStyle LibreLink app*



Available for people aged 4 and older with diabetes Use with the FreeStyle Libre 2 app⁺

The FreeStyle Libre portfolio of products is covered by most private insurance plans,[‡] and public funding is available in select provinces





life. to the fullest.

Abbott

T2D, type 2 diabetes.

- * The FreeStyle LibreLink app and the FreeStyle Libre reader have similar but not identical features. A finger prick test using a blood glucose meter is required during times of rapidly changing glucose levels when interstitial fluid glucose levels may not accurately reflect blood glucose levels or if hypoglycemia or impending hypoglycemia is reported by the FreeStyle LibreLink app or when symptoms do not match the app readings. The FreeStyle LibreLink app that started it. A sensor started by the FreeStyle Libre reader will also communicate with the FreeStyle LibreLink app. The FreeStyle LibreLink app is only compatible with certain mobile devices and operating systems. Please check the website for more information about device compatibility before using the app. Use of FreeStyle LibreLink requires registration with LibreView.
- † The FreeStyle Libre 2 app and the FreeStyle Libre 2 reader have similar but not identical features. Finger pricks are required if readings do not match symptoms or expectations. The FreeStyle Libre 2 sensor communicates with the FreeStyle Libre 2 app that started it. The FreeStyle Libre 2 app is only compatible with certain mobile devices and operating systems. Please check the website for more information about device compatibility before using the app. Use of FreeStyle Libre 2 requires registration with LibreView.

‡ Individual private drug plans can vary. Please have your patients check with their plan administrator and/or insurance company.

© 2022 Abbott. FreeStyle, Libre, and related brand marks are marks of Abbott. Product images are for illustrative purposes only. Other trademarks are the property of their respective owners. ADC-50648